Aspirin-exacerbated respiratory disease (AERD) is a disorder of nasal polyposis, asthma, and hypersensitivity respiratory reactions when on systemic cyclooxygenase 1 blockade.
Methods
AERD Warrants Specific Evaluation As An Endotype Of Asthma And Chronic Sinus Disease Due To Unique Therapeutic Opportunities. Currently, Aspirin Therapy Is Uniquely Beneficial As An Anti-Inflammatory Therapy In Aerd, With Multiple Additional Therapies Currently In Early To Late Clinical Studies, Which Might Also Show Exceptional Benefit In AERD.
Results
Yet, given the lack of a simple diagnostic test, opportunities to identify patients with AERD are still frequently neglected.
Conclusion
Identifying the prevalence and population characteristics necessary to determine appropriate candidates in whom to perform diagnostic aspirin challenge remains critically important and was the purpose of this article.
Get full access to this article
View all access options for this article.
References
1.
WidalF., AbramiP., and LermoyezJ.. Anaphylaxie et idiosyncrasie.La Presse Medícale30: 189–193, 1922.
2.
SamterM., and BeersR.F.. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis.Ann Intern Med68: 975–983, 1968.
3.
KimJ.E., and KountakisS.E.. The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery.Ear Nose Throat J86: 396–399, 2007.
4.
LeeJ.H., HaselkornT., BorishL.. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: Insights from the TENOR study.Chest132: 1882–1889, 2007.
5.
MasciaK., HaselkornT., DenizY.M.. Aspirin sensitivity and severity of asthma: Evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma.J Allergy Clin Immunol116: 970–975, 2005.
6.
KogaT., OshitaY., KamimuraT.. Characterisation of patients with frequent exacerbation of asthma.Respir Med100: 273–278, 2006.
7.
HedmanJ., KaprioJ., PoussaT., and NieminenM.M.. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study.Int J Epidemiol28: 717–722, 1999.
8.
WeberR.W., HoffmanM., RaineD.A.Jr.. Incidence of bronchoc-onstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics.J Allergy Clin Immunol64: 32–37, 1979.
9.
JenkinsC., CostelloJ., and HodgeL.. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice.BMJ328: 434, 2004.
RajanJ.P., WineingerN.E., StevensonD.D.. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature.J Allergy Clin Immunol135: 676–681.e1, 2015.
12.
MoralesD.R., GuthrieB., LipworthB.J.. NSAID-exacerbated respiratory disease: A meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity.Allergy70: 828–835, 2015.
13.
WhiteA.A., StevensonD.D., and SimonR.A.. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease.Ann Allergy Asthma Immunol95: 330–335, 2005.
14.
SzczeklikA., NizankowskaE., and DuplagaM.. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma.Eur Respir J16: 432–436, 2000.
15.
DursunA.B., WoessnerK.A., SimonR.A.. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis.Ann Allergy Asthma Immunol100: 420–425, 2008.
16.
WhiteA.A., BossoJ.V., and StevensonD.D.. The clinical dilemma of “silent desensitization” in aspirin-exacerbated respiratory disease.Allergy Asthma Proc34: 378–382, 2013.
17.
IsraelE., FischerA.R., RosenbergM.A.. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.Am Rev Respir Dis148(pt. 1): 1447–1451, 1993.
18.
AksuK., and KurtE.. Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease.Allergol Immunopathol (Madr)41: 208–210, 2013.
19.
CelikelS., StevensonD., ErkorkmazU., and WhiteA.A.. Use of nasal inspiratory flow rates in the measurement of aspirin-induced respiratory reactions.Ann Allergy Asthma Immunol111: 252–255, 2013.
20.
CookK.A., ModenaB.D., WineingerN.E.. Use of a composite symptom score during challenge in patients with suspected aspirinexacerbated respiratory disease.Ann Allergy Asthma Immunol118: 597–602, 2017.
21.
PayneS.C., EarlyS.B., HuyettP.. Evidence for distinct histologic profile of nasal polyps with and without eosinophilia.Laryngoscope121: 2262–2267, 2011.
22.
CowburnA.S., SladekK., SojaJ.. Overexpression of leukotriene C-4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.J Clin Invest101: 834–846, 1998.
23.
SteinkeJ.W., and BorishL.. Factors driving the aspirin exacerbated respiratory disease phenotype.Am J Rhinol Allergy29: 35–40, 2015.
24.
FanY., FengS., XiaW.. Aspirin-exacerbated respiratory disease in China: A cohort investigation and literature review.Am J Rhinol Allergy26: e20–e22, 2012.
25.
MahdaviniaM., SuhL.A., CarterR.G.. Increased noneosinophilic nasal polyps in chronic rhinosinusitis in US second-generation Asians suggest genetic regulation of eosinophilia.J Allergy Clin Immunol135: 576–579, 2015.
26.
CaoP.P., LiH.B., WangB.F.. Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese.J Allergy Clin Immunol124: 478–484, 484.e1-e2, 2009.
27.
MasciaK., BorishL., PatrieJ.. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease.Ann Allergy Asthma Immunol94: 652–657, 2005.
28.
CardetJ.C., WhiteA.A., BarrettN.A.. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease.J Allergy Clin Immunol Pract2: 208–213, 2014.
29.
StevensonD.D., PleskowW.W., SimonR.A.. Aspirin-sensitive rhinosinusitis asthma: A double-blind crossover study of treatment with aspirin.J Allergy Clin Immunol73: 500–507, 1984.
30.
FruthK., PogorzelskiB., SchmidtmannI.. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease.Allergy68: 659–665, 2013.
31.
EsmaeilzadehH., NabaviM., AryanZ.. Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.Clin Immunol160: 349357, 2015.
32.
Świerczyńska-KrěpaM., SanakM., BochenekG.. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: A double-blind study.J Allergy Clin Immunol134: 883–890, 2014.
